Whittemore Tingley, Chief Medical Officer of Tenaya Therapeutics, Inc. (NASDAQ:TNYA), filed a Form 4 on November 18, 2026, disclosing the sale of 3,223 shares of common stock on November 17, 2026, to cover tax withholding obligations tied to the vesting of restricted stock units.
Key Highlights
- Sale transaction: 3,223 shares of Tenaya Therapeutics common stock were disposed of on November 17, 2026, at a price of $0.3208 per share.
- Purpose of sale: According to the filing, the shares sold represent "the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units."
- Automatic transaction: The filing states the sales "were automatic and not at the discretion of the Reporting Person."
- RSU award date: The restricted stock units that vested were awarded on January 24, 2025.
- Beneficial ownership following transaction: Whittemore beneficially owned 259,850 shares following the reported transaction, held directly.
- Unvested shares included: The post-transaction total includes 134,157 shares of common stock that will be issued upon vesting of restricted stock, according to the filing.
Whittemore RSU Tax-Withholding Sale at Tenaya Therapeutics
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Chief Medical Officer Whittemore Tingley reported the disposal of 3,223 shares of company common stock on November 17, 2026, according to a Form 4 filed with the SEC on November 18, 2026. The transaction code recorded was "S," indicating a sale. The shares were sold at $0.3208 per share.
The filing specifies that the sale was not discretionary. It states the shares sold represent "the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on January 24, 2025," and that "such sales were automatic and not at the discretion of the Reporting Person." The transaction is reported as a direct ownership disposition in Table I of the filing.
Following the reported transaction, Whittemore's total direct beneficial ownership stood at 259,850 shares. The filing notes that this figure includes 134,157 shares of Tenaya Therapeutics common stock that will be issued upon the future vesting of restricted stock. The Form 4 was signed by Jennifer Drimmer Rokovich as Attorney-in-Fact on November 18, 2026. No derivative securities transactions were reported in Table II of the filing.
What Was Disclosed
Tenaya Therapeutics Chief Medical Officer Whittemore Tingley disclosed an automatic sale of 3,223 shares at $0.3208 on November 17, 2026, solely to satisfy tax withholding on vesting restricted stock units, leaving a reported beneficial ownership of 259,850 shares.



Please wait processing your request...